Navigation Links
ThromboGenics Announces Half Year Results 2008
Date:8/28/2008

LEUVEN, Belgium, August 28 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its financial results for the six month period ending June 30, 2008.

During the first half of 2008, ThromboGenics has achieved a number of key milestones which have positioned the Company to successfully pursue the next stage of its corporate strategy. In this period, ThromboGenics signed a high value strategic alliance with Roche for its novel anti-cancer product TB-403 and has seen important new clinical data for its lead product, microplasmin, in patients with back of the eye disease. Given this progress, ThromboGenics is confident that the next twelve months will see further significant shareholder value being generated as it continues to maximise value from its product pipeline.
2008 highlights

Partnership

- Major partnering deal: In June, ThromboGenics and its co-development

partner BioInvent signed a strategic alliance deal with Roche for its

novel anti-cancer agent, TB-403 (anti-PIGF). Under the terms of the

agreement ThromboGenics and BioInvent received an upfront payment of

EUR50 million and could potentially share up to EUR450 million in

milestone payments as well as double digit royalties. TB-403 is a novel

monoclonal antibody which blocks Placental Growth Factor (PIGF), one of

the growth factors responsible for the development of new blood

vessels. TB-403 is being developed as an anti-cancer agent, and is

currently in Phase I of clinical development. It acts by selectively

inhibiting tumor growth by blocking its blood supply without affecting

normal tissues.

Clinical Highlights

- TB-403 : Positive results announced in first Phase Ia study

with TB-403 and start of Phase Ib study in late stage cance
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
2. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
3. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
4. ThromboGenics N.V. - Business Update
5. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
6. ThromboGenics Announces 2007 Full Year Results
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
9. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
10. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
11. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... The report “Service Quality Management ... Product Type & Provider Type - Global ... and segments the market with an in-depth ... Browse 152 market data tables, 19 figures ... on “Service Quality Management (SQM) and Telco ...
(Date:12/24/2014)... SILVER SPRING, Md. , Dec. 24, 2014 ... ) announced today that Medtronic, Inc. (NYSE: ... application to the U.S. Food and Drug Administration ... II implantable drug infusion system (including a ... Remodulin ® (treprostinil) Injection delivered intravenously to ...
(Date:12/24/2014)... NEW YORK , Dec. 24, 2014 /PRNewswire/ ... company advancing patient care in critical areas, announced the ... of common stock, and warrants to purchase up to ... offering price of $4.00 per share and $.01 per ... of $5.00, are exercisable immediately, and expire 5 years ...
(Date:12/24/2014)... , Dec. 24, 2014  Vermillion, Inc. (Nasdaq: ... gynecologic disease, announced today that the Company closed ... Oracle Investment Management, Jack W. Schuler , ... proceeds were $10.5 million, before offering expenses.  The ... general corporate purposes. Under the terms ...
Breaking Biology Technology:Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 2Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 3Service Quality Management Market worth $2.1 Billion & Telco Customer Experience Management Market worth $2.3 Billion by 2019 – New Report by MarketsandMarkets 4United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3Vermillion Announces Closing of Equity Financing 2Vermillion Announces Closing of Equity Financing 3
... PRA, a leading Clinical Research Organization, continues our expansion ... of an office in Singapore. The office will serve ... strengthening the quality and timeliness of our deliverables to ... the heart of the city-state, will provide monitoring, project ...
... PARK, Calif., Feb. 23, 2012 Telome Health, Inc.™, ... telomere biology in human health, has announced that co-founder and ... Year by Silicon Valley Business Journal. ... award, especially coming from the heart of innovation, Silicon Valley, ...
... Calif., Feb. 21, 2012 Keck Graduate Institute (KGI) ... (CGS) and the Alfred P. Sloan Foundation to administer ... part of establishing and maintaining high quality standards for ... honored to be selected and we look forward to ...
Cached Biology Technology:PRA Opens Office in Singapore 2Telome Health Co-founder and Nobel Laureate Elizabeth Blackburn Awarded Innovator of the Year 2KGI Selected to Administer PSM Affiliation Process 2
(Date:12/24/2014)... NEW YORK , Dec. 23, 2014  Since its ... has helped thousands of people to eliminate the pain ... replacing the antiquated system with their own biometrics fused ... to remember usernames and passwords, Hoyos Labs , ... identity, announced today that it is offering the app ...
(Date:12/22/2014)... SHELTON, Conn. , Dec. 22, 2014  NXT-ID, ... or the "Company"), a biometric authentication company focused on ... famous pickpocket, entertainer and security consultant, Apollo Robbins ... Wocket™ biometric smart wallet.  Apollo ... 6th and 7 th , 2015, demonstrating some of ...
(Date:12/22/2014)... Dec. 22, 2014 Research and Markets ... the addition of the "The Global ... their offering. ... an overview of the global digital media ... control and monitor piracy by securely and ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 2NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 3NXT-ID Hires Master Pickpocket and Security Consultant Apollo Robbins for Wocket Smart Wallet CES 2015 Debut 4The Global Watermarking and Fingerprinting Markets 2
... Atlantis rockets into space later this week, it will ... study how their genetic responses and their ability to ... part of the STS-115 space shuttle mission scheduled for ... Salmonella typhimurium, Pseudomonas aeruginosa and Candida albicans -- that ...
... Virginia Health System have shown for the first time ... muscle cells can reverse myotonic dystrophy, the most common ... 40,000 people in the United States have myotonic muscular ... wasting of the muscles, irregular heartbeat, cataracts and insulin ...
... the Rubeho Mountains in Tanzania revealed over 160 ... eleven endemic species--according to an article published in ... findings elevate the importance of protecting this biologically-rich ... range from destructive activities underway such as clear-cutting ...
Cached Biology News:Microscopic passengers to hitch ride on space shuttle 2Microscopic passengers to hitch ride on space shuttle 3Toxic molecule may cause most common type of muscular dystrophy 2First surveys of Tanzanian mountains reveal 160+ animal species, including new & endemic 2
...
... The ideal modular cleanroom for biological ... that require cleanliness (to Class 10/ISO ... precision-joined to create ultra-smooth surfaces that ... disinfect. One-inch radius corners simplify cleaning. ...
This free-standing work station safely ventilates fumes upwards, away from the work surface. Optional Exhaust Purification System features bonded charcoal filters that remove organic chemical vapors ...
... Analysis Note: Protein determined by ... 3.2 M (NH 4 ) ... 7.0 Preparation Note: Affinity purified ... suspension • Additives: MgCl 2 ...
Biology Products: